XML 19 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Treasury Stock
Retained Earnings
Accumulated Other Comprehensive Loss
Beginning balance at Apr. 30, 2023 $ 37,409 $ 7,084 $ 5,059 $ (53) $ 28,761 $ (3,442)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings attributable to Kewaunee Scientific Corporation 2,474       2,474  
Other comprehensive loss (144)         (144)
Stock-based compensation (309) 185 (494)      
Ending balance at Jul. 31, 2023 39,430 7,269 4,565 (53) 31,235 (3,586)
Beginning balance at Apr. 30, 2023 37,409 7,084 5,059 (53) 28,761 (3,442)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings attributable to Kewaunee Scientific Corporation 7,727          
Other comprehensive loss (435)          
Ending balance at Jan. 31, 2024 44,083 7,270 5,046 (844) 36,488 (3,877)
Beginning balance at Jul. 31, 2023 39,430 7,269 4,565 (53) 31,235 (3,586)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings attributable to Kewaunee Scientific Corporation 2,732       2,732  
Other comprehensive loss (251)         (251)
Stock-based compensation 241   241      
Purchase of Treasury Stock (44)     (44)    
Ending balance at Oct. 31, 2023 42,108 7,269 4,806 (97) 33,967 (3,837)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings attributable to Kewaunee Scientific Corporation 2,521       2,521  
Other comprehensive loss (40)         (40)
Stock-based compensation 241 1 240      
Purchase of Treasury Stock (747)     (747)    
Ending balance at Jan. 31, 2024 44,083 7,270 5,046 (844) 36,488 (3,877)
Beginning balance at Apr. 30, 2024 54,760 7,273 5,406 (2,051) 47,514 (3,382)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings attributable to Kewaunee Scientific Corporation 2,193       2,193  
Other comprehensive loss (116)         (116)
Stock-based compensation (814) 80 (894)      
Ending balance at Jul. 31, 2024 56,023 7,353 4,512 (2,051) 49,707 (3,498)
Beginning balance at Apr. 30, 2024 54,760 7,273 5,406 (2,051) 47,514 (3,382)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings attributable to Kewaunee Scientific Corporation 6,555          
Other comprehensive loss (454)          
Ending balance at Jan. 31, 2025 60,801 7,353 5,266 (2,051) 54,069 (3,836)
Beginning balance at Jul. 31, 2024 56,023 7,353 4,512 (2,051) 49,707 (3,498)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings attributable to Kewaunee Scientific Corporation 3,008       3,008  
Other comprehensive loss (76)         (76)
Stock-based compensation 373   373      
Ending balance at Oct. 31, 2024 59,328 7,353 4,885 (2,051) 52,715 (3,574)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net earnings attributable to Kewaunee Scientific Corporation 1,354       1,354  
Other comprehensive loss (262)         (262)
Stock-based compensation 381   381      
Ending balance at Jan. 31, 2025 $ 60,801 $ 7,353 $ 5,266 $ (2,051) $ 54,069 $ (3,836)